Trials / Approved For Marketing
Approved For MarketingNCT01858103
BMN 110 US Expanded Access Program
A Multicenter, Open-label BMN 110 US Expanded Access Program (BMN 110 US EAP) to Provide BMN 110 to Patients Diagnosed With MPS IVA
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- BioMarin Pharmaceutical · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
The Expanded Access Program (EAP) is an open-label, multicenter program to: 1. Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA) access to BMN 110 until commercial product is available 2. Collect additional information on the safety and tolerability of BMN 110 administration in patients with MPS IVA Patients enrolled in the EAP will receive 2.0 mg/kg intravenous infusions of BMN 110 every week during the program.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMN 110 |
Timeline
- First posted
- 2013-05-21
- Last updated
- 2014-04-02
Locations
25 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT01858103. Inclusion in this directory is not an endorsement.